Premium
Identification of two novel LDL receptor gene defects in French‐Canadian pediatric population: Mutational analysis and biochemical studies
Author(s) -
Assouline Linda,
Leitersdorf Eran,
Lambert Marie,
Reshef Ayeleth,
FeoliFonseca Juan C.,
Levy Emile
Publication year - 1997
Publication title -
human mutation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.981
H-Index - 162
eISSN - 1098-1004
pISSN - 1059-7794
DOI - 10.1002/(sici)1098-1004(1997)9:6<555::aid-humu9>3.0.co;2-0
Subject(s) - biology , genetics , frameshift mutation , exon , mutation , familial hypercholesterolemia , compound heterozygosity , population , stop codon , gene duplication , gene , microbiology and biotechnology , endocrinology , cholesterol , medicine , environmental health
Familial hypercholesterolemia (FH) is at least twofold more prevalent in French Canadians from Québec than in most Western populations. Although our recent data confirmed this high frequency of heterozygous FH in our pediatric population with hypercholesterolemia, none of the five established molecular defects for the French‐Canadian population was detected in 29% of the unrelated French‐Canadian children characterized by a persistent increase in LDL (low density lipoprotein receptor) cholesterol and a positive parental history of hyperlipidemia (Assouline et al., 1995). To probe for new mutations, six of these molecularly undiagnosed children were investigated as index patients. By using single‐strand conformation polymorphism analysis and DNA sequencing, two novel mutations were identified in two of these subjects: (1) 7‐base pair (bp) duplication following nucleotide 681 (according to the cDNA sequence) in exon 4 (681ins7), which causes a frameshift, the introduction of a stop at codon 208, and premature chain termination, and (2) A to G change in exon 8 substituting a tyrosine for a cysteine at amino acid 354 (Y354C). A third subject carried the recently reported exon 10 mutation (Y468X), whereas the remaining three patients demonstrated various known polymorphisms with no effect on gene product. Rapid molecular assays were developed to detect the two new mutations as well as the Y468X mutation. Screening of our cohort showed heterozygosity in 1/88, in 2/88, and in 2/88 of patients for the 681ins7, the Y354C, and the Y468X mutations, respectively. Hum. Mutat. 9:555–562, 1997. © 1997 Wiley‐Liss, Inc.